← Back to Search

Social Support for Breast Cancer Survivors (JLA Trial)

N/A

Waitlist Available

Led By Qian Lu, PhD; MD

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Having a first breast cancer diagnosis of stages 0-III

Be older than 18 years old

Must not have

Breast cancer diagnosis of stage IV

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline before intervention and immediately, 1 month, and 4 months after the intervention

Awards & highlights

No Placebo-Only Group

Summary

This trial will investigate how a program called Joy Luck Academy can help Chinese American breast cancer survivors by providing them with culturally relevant social support.

Who is the study for?

This trial is for Chinese American breast cancer survivors who are comfortable speaking Mandarin or Cantonese, have had a first diagnosis of stages 0-III breast cancer, and completed primary treatment within the last 36 months.

What is being tested?

The study tests a culturally based social support program called Joy Luck Academy (JLA) to see how it affects Chinese American women who've survived breast cancer. It's a randomized controlled trial, meaning participants are randomly assigned to receive JLA or not.

What are the potential side effects?

Since this intervention involves social support rather than medication, traditional physical side effects aren't expected. Emotional discomfort due to sharing experiences could occur.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My first breast cancer diagnosis was at stage 0 to III.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

My breast cancer is at stage IV.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline before intervention and immediately, 1 month, and 4 months after the intervention

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline before intervention and immediately, 1 month, and 4 months after the intervention

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline before intervention and immediately, 1 month, and 4 months after the intervention for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Secondary study objectives

Change in depressive symptoms as assessed by CES-D

Change in fatigue as assessed by FACIT

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Social support intervention groupExperimental Treatment1 Intervention

The intervention is a 7-week program includes educational and peer mentoring support components. The education curriculum provides information on recognizing side effects of treatment and differentiating them from symptoms of cancer recurrence, physical therapy and alternative treatment, stress management, recognizing depression and managing emotional problems, communication with family members, and body image. The peer-support component assigns each participant with a mentor who is a breast cancer survivor. They share their own experience with participants and also make weekly phone calls to mentees during the intervention to provide support and address remaining concerns.

Group II: Enhanced care and wait-list control groupActive Control1 Intervention

Participants in the control group will receive enhanced usual care while waiting for the JLA program. Participants will be given information booklets in Chinese developed by the American Cancer Society and cover common issues related to breast cancer, various treatments, and life after treatment. Participants will be asked to read through the booklet individually.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Social support intervention

2015

N/A

~170

0 / 2Eligibility criteria met